Global Capecitabine Market Insights and Forecast to 2026 by Top Companies
出 版 商：XYZ Research
出版日期：2019/12/01
頁 數：103頁
文件格式：PDF
價 格：
USD 3,150 (Single-User License)
USD 6,200 (Global-User License)
USD 6,200 (Global-User License)
In this report,global Capecitabine Market will reach 1031.47 Million USD by the end of 2022 with a CAGR of -0.17%
The global Capecitabine market is valued at 1040.38 Million USD in 2017 and will reach 1031.47 Million USD by the end of 2022, growing at a CAGR of -0.17% during 2017-2022.
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Capecitabine can be divided into two categories—500 mg type and 150 mg type. 500 mg type production market share accounted for the highest proportion, with a figure of 67.42% in 2017, regenerative type account for 32.58%.
The consumption market share of global Capecitabine in Breast Cancer use, Colorectal cancer use and Stomach Cancer use have been stable year by year, at 40.16%, 31.01% and 28.83% respectively in 2017, and for several consecutive years, the amplitude was within one percent. This indicates that the segment of the Capecitabine in the global market tends to be fixed without great changes. Among them, the Capecitabine market has the most promising sales prospects in Breast Cancer use.
XYZ research center data shows that North America is the biggest contributor to the Capecitabine revenue market, accounted for 54.53% of the total global market with a revenue of 567.37 million USD in 2017, followed by Europe, 28.92% with a revenue of 300.91 million USD.
Roche is the largest company in the global Capecitabine market, accounted for 62.81% of the revenue market share in 2017, followed by Teva and Mylan, accounted for 15.60% and 9.94% of the revenue market share in 2017. These manufacturers range from large multinational corporations to small privately owned companies compete in this industry. The top four producers account for above 90% of the revenue market.
All manufactures in the world are committed to the improvement of product. These two years, some of Chinese and India manufactures can almost catch up with the world's leading technology too. Most technologies are developed by the manufacturers instead of importing from other companies.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Capecitabine in these regions, from 2014 to 2026 (forecast), covering
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
South America (Brazil, Argentina, Columbia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Capecitabine market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Other
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
150mg
500mg
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Capecitabine for each application, including
Breast Cancer
Colorectal Cancer
Stomach Cancer
If you have any special requirements, please let us know and we will offer you the report as you want.
The global Capecitabine market is valued at 1040.38 Million USD in 2017 and will reach 1031.47 Million USD by the end of 2022, growing at a CAGR of -0.17% during 2017-2022.
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Capecitabine can be divided into two categories—500 mg type and 150 mg type. 500 mg type production market share accounted for the highest proportion, with a figure of 67.42% in 2017, regenerative type account for 32.58%.
The consumption market share of global Capecitabine in Breast Cancer use, Colorectal cancer use and Stomach Cancer use have been stable year by year, at 40.16%, 31.01% and 28.83% respectively in 2017, and for several consecutive years, the amplitude was within one percent. This indicates that the segment of the Capecitabine in the global market tends to be fixed without great changes. Among them, the Capecitabine market has the most promising sales prospects in Breast Cancer use.
XYZ research center data shows that North America is the biggest contributor to the Capecitabine revenue market, accounted for 54.53% of the total global market with a revenue of 567.37 million USD in 2017, followed by Europe, 28.92% with a revenue of 300.91 million USD.
Roche is the largest company in the global Capecitabine market, accounted for 62.81% of the revenue market share in 2017, followed by Teva and Mylan, accounted for 15.60% and 9.94% of the revenue market share in 2017. These manufacturers range from large multinational corporations to small privately owned companies compete in this industry. The top four producers account for above 90% of the revenue market.
All manufactures in the world are committed to the improvement of product. These two years, some of Chinese and India manufactures can almost catch up with the world's leading technology too. Most technologies are developed by the manufacturers instead of importing from other companies.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Capecitabine in these regions, from 2014 to 2026 (forecast), covering
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
South America (Brazil, Argentina, Columbia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Capecitabine market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Other
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
150mg
500mg
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Capecitabine for each application, including
Breast Cancer
Colorectal Cancer
Stomach Cancer
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
Global Capecitabine Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Capecitabine Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 150mg Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 500mg Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Capecitabine Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Capecitabine Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Capecitabine Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Capecitabine Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Capecitabine Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Capecitabine Market Assessment by Type
8.1 Asia Pacific Capecitabine Market Assessment by Application (Consumption and Market Share)
8.2 North America Capecitabine Market Assessment by Application (Consumption and Market Share)
8.3 Europe Capecitabine Market Assessment by Application (Consumption and Market Share)
8.4 South America Capecitabine Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Capecitabine Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Roche
9.1.1 Roche Profiles
9.1.2 Roche Product Portfolio
9.1.3 Roche Capecitabine Business Performance
9.1.4 Roche Capecitabine Business Development and Market Status
9.2 Teva
9.2.1 Teva Profiles
9.2.2 Teva Product Portfolio
9.2.3 Teva Capecitabine Business Performance
9.2.4 Teva Capecitabine Business Development and Market Status
9.3 Mylan
9.3.1 Mylan Profiles
9.3.2 Mylan Product Portfolio
9.3.3 Mylan Capecitabine Business Performance
9.3.4 Mylan Capecitabine Business Development and Market Status
9.4 Hikma
9.4.1 Hikma Profiles
9.4.2 Hikma Product Portfolio
9.4.3 Hikma Capecitabine Business Performance
9.4.4 Hikma Capecitabine Business Development and Market Status
9.5 Hengrui Medicine
9.5.1 Hengrui Medicine Profiles
9.5.2 Hengrui Medicine Product Portfolio
9.5.3 Hengrui Medicine Capecitabine Business Performance
9.5.4 Hengrui Medicine Capecitabine Business Development and Market Status
9.6 Cipla
9.6.1 Cipla Profiles
9.6.2 Cipla Product Portfolio
9.6.3 Cipla Capecitabine Business Performance
9.6.4 Cipla Capecitabine Business Development and Market Status
9.7 Reliance Group
9.7.1 Reliance Group Profiles
9.7.2 Reliance Group Product Portfolio
9.7.3 Reliance Group Capecitabine Business Performance
9.7.4 Reliance Group Capecitabine Business Development and Market Status
9.8 Hetero
9.8.1 Hetero Profiles
9.8.2 Hetero Product Portfolio
9.8.3 Hetero Capecitabine Business Performance
9.8.4 Hetero Capecitabine Business Development and Market Status
9.9 Other
9.9.1 Other Profiles
9.9.2 Other Product Portfolio
9.9.3 Other Capecitabine Business Performance
9.9.4 Other Capecitabine Business Development and Market Status
10 World Capecitabine Market Assessment by Players
10.1 Global Capecitabine Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Capecitabine Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Capecitabine Price (USD/Unit) of Players 2014-2020
10.4 Global Capecitabine Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Capecitabine Sales Assessment of Players 2014-2020
11.1.2 North America Capecitabine Revenue Assessment of Players 2014-2020
11.1.3 North America Capecitabine Price Assessment of Players 2014-2020
11.1.4 North America Capecitabine Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Capecitabine Sales Assessment of Players 2014-2020
11.2.2 Europe Capecitabine Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Capecitabine Price Assessment of Players 2014-2020
11.2.4 Europe Capecitabine Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Capecitabine Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Capecitabine Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Capecitabine Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Capecitabine Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Capecitabine Sales Assessment of Players 2014-2020
11.4.2 South America Capecitabine Revenue Assessment of Players 2014-2020
11.4.3 South America Capecitabine Price Assessment of Players 2014-2020
11.4.4 South America Capecitabine Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Capecitabine Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Capecitabine Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Capecitabine Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Capecitabine Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Capecitabine Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Capecitabine Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Capecitabine Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Capecitabine Sales by Countries/Regions 2014-2020
12.2.2 North America Capecitabine Revenue by Countries/Regions 2014-2020
12.2.3 North America Capecitabine Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Capecitabine Sales by Countries/Regions 2014-2020
12.3.2 Europe Capecitabine Revenue by Countries/Regions 2014-2020
12.3.3 Europe Capecitabine Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Capecitabine Sales by Countries/Regions 2014-2020
12.4.2 South America Capecitabine Revenue by Countries/Regions 2014-2020
12.4.3 South America Capecitabine Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Capecitabine Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Capecitabine Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Capecitabine Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Capecitabine Sales & Revenue Forecast 2021-2026
14.1 World Capecitabine Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World CapecitabineSales and Market Share by Regions
14.1.2 World CapecitabineRevenue and Market Share by Regions
15 Asia Capecitabine Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 150mg
15.1.2 500mg
15.2 Consumption Forecast by Application, 2021-2026
16 North America Capecitabine Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 150mg
16.1.2 500mg
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Capecitabine Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 150mg
17.1.2 500mg
17.2 Consumption Forecast by Application, 2021-2026
18 South America Capecitabine Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 150mg
18.1.2 500mg
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Capecitabine Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 150mg
19.1.2 500mg
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Capecitabine Price (USD/Unit) Trend 2021-2026
20.2 Global Capecitabine Gross Profit Trend 2021-2026
21 Conclusion
Global Capecitabine Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Capecitabine Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 150mg Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 500mg Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Capecitabine Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Capecitabine Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Capecitabine Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Capecitabine Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Capecitabine Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Capecitabine Market Assessment by Type
8.1 Asia Pacific Capecitabine Market Assessment by Application (Consumption and Market Share)
8.2 North America Capecitabine Market Assessment by Application (Consumption and Market Share)
8.3 Europe Capecitabine Market Assessment by Application (Consumption and Market Share)
8.4 South America Capecitabine Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Capecitabine Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Roche
9.1.1 Roche Profiles
9.1.2 Roche Product Portfolio
9.1.3 Roche Capecitabine Business Performance
9.1.4 Roche Capecitabine Business Development and Market Status
9.2 Teva
9.2.1 Teva Profiles
9.2.2 Teva Product Portfolio
9.2.3 Teva Capecitabine Business Performance
9.2.4 Teva Capecitabine Business Development and Market Status
9.3 Mylan
9.3.1 Mylan Profiles
9.3.2 Mylan Product Portfolio
9.3.3 Mylan Capecitabine Business Performance
9.3.4 Mylan Capecitabine Business Development and Market Status
9.4 Hikma
9.4.1 Hikma Profiles
9.4.2 Hikma Product Portfolio
9.4.3 Hikma Capecitabine Business Performance
9.4.4 Hikma Capecitabine Business Development and Market Status
9.5 Hengrui Medicine
9.5.1 Hengrui Medicine Profiles
9.5.2 Hengrui Medicine Product Portfolio
9.5.3 Hengrui Medicine Capecitabine Business Performance
9.5.4 Hengrui Medicine Capecitabine Business Development and Market Status
9.6 Cipla
9.6.1 Cipla Profiles
9.6.2 Cipla Product Portfolio
9.6.3 Cipla Capecitabine Business Performance
9.6.4 Cipla Capecitabine Business Development and Market Status
9.7 Reliance Group
9.7.1 Reliance Group Profiles
9.7.2 Reliance Group Product Portfolio
9.7.3 Reliance Group Capecitabine Business Performance
9.7.4 Reliance Group Capecitabine Business Development and Market Status
9.8 Hetero
9.8.1 Hetero Profiles
9.8.2 Hetero Product Portfolio
9.8.3 Hetero Capecitabine Business Performance
9.8.4 Hetero Capecitabine Business Development and Market Status
9.9 Other
9.9.1 Other Profiles
9.9.2 Other Product Portfolio
9.9.3 Other Capecitabine Business Performance
9.9.4 Other Capecitabine Business Development and Market Status
10 World Capecitabine Market Assessment by Players
10.1 Global Capecitabine Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Capecitabine Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Capecitabine Price (USD/Unit) of Players 2014-2020
10.4 Global Capecitabine Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Capecitabine Sales Assessment of Players 2014-2020
11.1.2 North America Capecitabine Revenue Assessment of Players 2014-2020
11.1.3 North America Capecitabine Price Assessment of Players 2014-2020
11.1.4 North America Capecitabine Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Capecitabine Sales Assessment of Players 2014-2020
11.2.2 Europe Capecitabine Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Capecitabine Price Assessment of Players 2014-2020
11.2.4 Europe Capecitabine Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Capecitabine Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Capecitabine Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Capecitabine Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Capecitabine Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Capecitabine Sales Assessment of Players 2014-2020
11.4.2 South America Capecitabine Revenue Assessment of Players 2014-2020
11.4.3 South America Capecitabine Price Assessment of Players 2014-2020
11.4.4 South America Capecitabine Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Capecitabine Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Capecitabine Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Capecitabine Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Capecitabine Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Capecitabine Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Capecitabine Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Capecitabine Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Capecitabine Sales by Countries/Regions 2014-2020
12.2.2 North America Capecitabine Revenue by Countries/Regions 2014-2020
12.2.3 North America Capecitabine Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Capecitabine Sales by Countries/Regions 2014-2020
12.3.2 Europe Capecitabine Revenue by Countries/Regions 2014-2020
12.3.3 Europe Capecitabine Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Capecitabine Sales by Countries/Regions 2014-2020
12.4.2 South America Capecitabine Revenue by Countries/Regions 2014-2020
12.4.3 South America Capecitabine Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Capecitabine Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Capecitabine Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Capecitabine Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Capecitabine Sales & Revenue Forecast 2021-2026
14.1 World Capecitabine Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World CapecitabineSales and Market Share by Regions
14.1.2 World CapecitabineRevenue and Market Share by Regions
15 Asia Capecitabine Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 150mg
15.1.2 500mg
15.2 Consumption Forecast by Application, 2021-2026
16 North America Capecitabine Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 150mg
16.1.2 500mg
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Capecitabine Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 150mg
17.1.2 500mg
17.2 Consumption Forecast by Application, 2021-2026
18 South America Capecitabine Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 150mg
18.1.2 500mg
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Capecitabine Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 150mg
19.1.2 500mg
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Capecitabine Price (USD/Unit) Trend 2021-2026
20.2 Global Capecitabine Gross Profit Trend 2021-2026
21 Conclusion
